Sugi Predict

Sugi Predict / Compounds / SCHEMBL4305407

SCHEMBL4305407

SCHEMBL4305407

O=[N+]([O-])c1ccccc1OS(=O)(=O)Oc1ccccc1[N+](=O)[O-]

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.60
▸ TDP1 Q9NUW8 1/20 0.60
▸ NPC1 O15118 2/20 0.58
▸ RAB9A P51151 2/20 0.58
▸ RECQL P46063 1/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.53
▸ HPGD P15428 1/20 0.53
▸ KMT2A Q03164 5/20 0.52
▸ MEN1 O00255 3/20 0.52
▸ LMNA P02545 2/20 0.46
▸ MAPT P10636 1/20 0.46
▸ HTT P42858 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ KDM4E B2RXH2 1/20 0.45
▸ CA1 P00915 1/20 0.44
▸ CA2 P00918 1/20 0.44
▸ MMP1 P03956 1/20 0.44
▸ MMP2 P08253 1/20 0.44
▸ MMP9 P14780 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4054403 0.91 ALDH1A1 (0.51) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL8757579 0.89 ALDH1A1 (0.53) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL2333531 0.85 ALDH1A1 (0.56) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL3943254 0.85 ALDH1A1 (0.56) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL4102754 0.85 ALDH1A1 (0.61) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL3943250 0.85 ALDH1A1 (0.56) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL2501666 0.85 ALDH1A1 (0.56) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL31443947 0.85 ALDH1A1 (0.56) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL27494789 0.83 ALDH1A1 (0.59) ALDH1A1TDP1NPC1RAB9ARECQL
SCHEMBL11134429 0.82 KMT2A (0.59) ALDH1A1TDP1NPC1RAB9ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4182452-A1 METHODS FOR SYNTHESIZING NON-ANTICOAGULANT HEPARAN SULFATE Optimvia, LLC (US) 2023-05-24 — — EP claimed
EP-3997238-A1 METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES Optimvia, LLC (US) 2022-05-18 — — EP claimed
EP-3911737-A1 ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES Optimvia, LLC (US) 2021-11-24 — — EP claimed
WO-2021007429-A1 METHODS FOR SYNTHESIZING ANTICOAGULANT POLYSACCHARIDES OPTIMVIA LLC (US) 2021-01-14 — — WO claimed
WO-2020150350-A1 ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES OPTIMVIA, LLC (US) 2020-07-23 — — WO claimed
WO-2018175464-A1 ENZYMATIC PREPARATION OF INCREASED ANTICOAGULANT BOVINE SOURCED HEPARIN RENSSELAER POLYTECHNIC INSTITUTE (US) 2018-09-27 — — WO claimed
EP-2761017-A1 SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO MINOXIDIL FOR THE TREATMENT OF ANDROGENETIC ALOPECIA Follea International Limited (CN) 2014-08-06 — — EP claimed
WO-2013049258-A1 SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO MINOXIDIL FOR THE TREATMENT OF ANDROGENETIC ALOPECIA FOLLEA INTERNATIONAL (US) 2013-04-04 — — WO claimed
US-11939303-B2 Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives POLITECHNIKA GDANSKA (PL) 2024-03-26 — — US disclosed
US-20240076634-A1 ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES GINKGO BIOWORKS, INC. 2024-03-07 — — US disclosed
WO-2023239972-A1 MINOXIDIL ADJUVANT THERAPIES Jupiter Wellness, Inc. (US) 2023-12-14 — — WO disclosed
US-11773382-B2 Engineered aryl sulfate-dependent enzymes OPTIMVIA, LLC (US) 2023-10-03 — — US disclosed
US-11767518-B2 Engineered aryl sulfate-dependent enzymes OPTIMVIA, LLC (US) 2023-09-26 — — US disclosed
US-11708567-B2 Engineered aryl sulfate-dependent enzymes OPTIMVIA, LLC (US) 2023-07-25 — — US disclosed
WO-2013049258-A1 SYSTEMS AND METHODS FOR PREDICTING RESPONSE TO MINOXIDIL FOR THE TREATMENT OF ANDROGENETIC ALOPECIA FOLLEA INTERNATIONAL (US) 2013-04-04 — — WO disclosed
WO-2012071131-A1 METHODS AND COMPOSITIONS TO DETECT A BIOLOGICAL ACTIVITY 3M INNOVATIVE PROPERTIES COMPANY (US) 2012-05-31 — — WO disclosed
WO-2009134988-A1 SCREEN FOR INHIBITORS OF HIV REPLICATION WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2009-11-05 — — WO disclosed
EP-1402067-A4 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE EXELIXIS INC (US) 2005-04-27 — — EP disclosed
EP-1402067-A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE Exelixis, Inc. (US) 2004-03-31 — — EP disclosed
WO-2002099138-A2 HS2STs AS MODIFIERS OF THE P53 PATHWAY AND METHODS OF USE EXELIXIS, INC. (US) 2002-12-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939303-B2 Sulfamate derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, derivatives of 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenol, their medical use and the method of obtaining 4-(1-phenyl-1H-[1,2,3]triazol-4-yl)-phenyl sulfamate derivatives SULT1E1, SULT2A1, SULT1A1 ALDH1A1 507/4885TDP1 2518/4885NPC1 3499/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.